For the more than 1 million Americans who live with type 1 diabetes, daily insulin injections are literally a matter of life and death. And while there is no cure, a Cornell-led research team has developed a device that could revolutionize management of the disease.
In Type 1 diabetes, insulin-producing pancreatic cell clusters (islets) are destroyed by the body’s immune system. The research group, led by assistant professor Minglin Ma from the Department of Biological and Environmental Engineering in the College of Agriculture and Life Sciences, has devised an ingenious method for implanting hundreds of thousands of islet cells into a patient. They are protected by a thin hydrogel coating and, more importantly, the coated cells are attached to a polymer thread and can be removed or replaced easily when they have outlived their usefulness.
Doctoral students Duo An and Alan Chiu are co-lead authors of the group’s paper, “Designing a Retrievable and Scalable Cell Encapsulation Device for Potential Treatment of Type 1 Diabetes,” published Dec. 25 in Proceedings of the National Academy of Sciences.
An example of the “radical collaboration” concept that is a hallmark of Cornell research, this work also featured key contributions from: Dr. James Flanders from the College of Veterinary Medicine; professor Jintu Fan from the Department of Fiber Science & Apparel Design in the College of Human Ecology; and assistant professor Meredith Silberstein from the Department of Mechanical and Aerospace Engineering in the College of Engineering.
Transplantation of stem cell-derived, insulin-producing islet cells is an alternative to insulin therapy, but that requires long-term immunosuppressive drug administration. One well-researched approach to avoid the immune system’s response is to coat and protect the cells in tiny hydrogel capsules, hundreds of microns in diameter. However, these capsules cannot be taken out of the body easily, since they’re not connected to each other, and there are hundreds of thousands of them.
And the ability to remove the transplant is key because of the potential of tumors forming when stem cell-derived, insulin-producing cells – the most promising cell source for type 1 diabetes cell therapies – are used.
“When they fail or die, they need to come out,” Ma said. “You don’t want to put something in the body that you can’t take out. With our method, that’s not a problem.”
Taking inspiration from the way water beads on a spider’s web, Ma and his team first attempted to connect the islet cell-containing capsules through a string but realized that it would be better to put the hydrogel layer uniformly around a string instead.
That string: an ionized calcium-releasing, nanoporous polymer thread. The device starts with two sterile nylon sutures twisted in a helix, then folded over to facilitate the subsequent nanoporous structure coatings. Placed onto that thread is a thin layer of islet cell-containing alginate hydrogel, which adheres to the helical, nanoporous thread, similar to dew drops sticking to the spider silk. Alginate is a seaweed extract commonly used in encapsulated cell transplantation.
This thread – which the group has dubbed TRAFFIC (Thread-Reinforced Alginate Fiber For Islets enCapsulation) – was inspired by a spider’s web but, according to Ma, is even better because the hydrogel covers the thread uniformly.
“You don’t have any gaps between capsules,” he said. “With a spider’s silk, you still have gaps between the water beads. In our case, gaps would be bad in terms of scar tissue and the like.”
And since the thread is twisted and porous, the hydrogel won’t slip off as it would on a single, smooth piece of material. Fan and Silberstein were instrumental in modeling different options for the thread configuration.
This therapy would involve minimally invasive laparoscopic surgery to implant approximately six feet of hydrogel-coated thread into the patient’s peritoneal cavity.
“We only need two quarter-inch-long incisions,” Flanders said. “We inflate the abdomen with carbon dioxide, which gives us room to work, and then put in two ports – one for a scope that’s hooked to a camera, so we can see what we’re doing, and the other for a grasping device, which is how we introduce the implant.”
TRAFFIC’s large surface area promotes better mass transfer, Ma said, and diffusion is good because all the islet cells are near the surface. Current life span estimates for the thread are between six and 24 months, although more testing is necessary.
In mice, blood glucose levels were returned to normal two days after implantation of a one-inch length of TRAFFIC, and remained normal for at least three months when the experiment ended. Retrievability was tested in multiple dogs, with 10-inch samples being successfully implanted and removed laparoscopically.
Flanders, who performed surgical implantation in canines, said among the different dogs and devices tested there was either no or only minimal adhesion of the device to surrounding tissue upon removal.
This collaboration has produced a potentially game-changing medical device, he said.
“When Minglin first told me about this, I thought it was brilliant,” Flanders said. “There have been other devices sort of like this, but this one seems to have so much promise. It’s minimally reactive, it protects the islet cells, it allows them to sense glucose, they don’t attach to anything, and it can be easily removed. To me, it sounded like a win-win.”
Learn more: Removable implant may control type 1 diabetes
The Latest on: Type 1 diabetes
[google_news title=”” keyword=”type 1 diabetes” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Ask A Doctor: How Can We Prevent Diabetes Type 1?on May 14, 2024 at 6:02 am
Expert opinion from Sadhvi Mythili MBBS,DNB psychiatry · 6 years of experience · India It is understood that the body's immune system causes Type 1 diabetes. Currently, we don't have any knowledge on ...
- How Can We Prevent Diabetes Type 1? A Review By Doctorson May 14, 2024 at 4:10 am
Expert opinion from Rajesh Mishra MBBS · Less than a year of experience · India Currently, no one knows how to prevent type 1 diabetes, but it can be managed by following your doctor's recommendations ...
- Rock Type One event harnesses music in quest for diabetes cureon May 14, 2024 at 2:10 am
Rock Type One to None will happen at Dreamland Bar-B-Q at the Centre Of Tallahassee from 4-7 p.m. Saturday, May 18.
- 'DWTS' pro Rylee Arnold opens up on living with Type 1 diabetes: 'Taught me so much about myself'on May 13, 2024 at 9:37 am
"Dancing with the Stars" pro Rylee Arnold is opening up about living with diabetes, writing she is "incredibly grateful for the strength it has given me," in an Instagram post on Monday. Arnold ...
- Glucose Level Fluctuations Tied to Cognitive Impairment in Type 1 Diabeteson May 13, 2024 at 7:18 am
Researchers sought to determine the cognitive performance of patients with both low and high glucose levels, as well as identify the characteristics predictive of differences in cognitive ...
- Which Patients With Diabetes and Ketoacidosis Face Higher Death Risk?on May 12, 2024 at 3:22 pm
In the retrospective study, the mortality rate for those with T2D and diabetic ketoacidosis (DKA) came in at 0.85% versus 0.2% for those with T1D and DKA ( P
- Breakthrough treatment offers hope for Type 1 diabetes patientson May 10, 2024 at 8:42 pm
With Tzield offering newfound optimism for Type 1 diabetes patients, Holdt's story serves as a beacon of hope, illustrating the potential of medical advancements to enhance quality of life. Holdt said ...
- AVAnT1A study: Investigating early COVID-19 vaccination and type 1 diabetes risk in high-risk childrenon May 8, 2024 at 8:29 pm
Type 1 diabetes is an autoimmune disease that leads to disrupted glucose metabolism. It requires lifelong insulin therapy. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) ...
- Cell therapy fails to slow early type 1 diabetes, but safety is establishedon May 8, 2024 at 11:00 am
Despite the negative finding, researchers said there is still promise in the strategy of amplifying and infusing the immune cells of newly diagnosed type 1 diabetes patients.
- Don't Overlook Cardiovascular Risk in Type 1 Diabeteson May 8, 2024 at 7:56 am
Cardiovascular disease management is an often overlooked but critical aspect of care for people with type 1 diabetes, authors of a new review paper said. Cardiovascular disease is the most common ...
via Google News and Bing News